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Effectiveness of [124I]-PET/CT and [18F]-FDG-PET/CT for 
Localizing Recurrence in Patients with Differentiated Thyroid 
Carcinoma
Although the prognosis of patients with differentiated thyroid carcinoma (DTC) is generally 
encouraging, a diagnostic dilemma is posed when an increasing level of serum 
thyroglobulin (Tg) is noted, without detection of a recurrent tumor using conventional 
imaging tools such as the iodine-131 whole-body scanning (the [131I] scan) or neck 
ultrasonography (US). The objective of the present study was to evaluate the diagnostic 
value of [124I]-PET/CT and [18F]-FDG-PET/CT in terms of accurate detection of both iodine- 
and non-iodine-avid recurrence, compared with that of conventional imaging such as the 
[131I] scan or neck ultrasonography (US). Between July 2009 and June 2010, we 
prospectively studied 19 DTC patients with elevated thyroglobulin levels but who do not 
show pathological lesions when conventional imaging modalities are used. All involved 
patients had undergone total thyroidectomy and radioiodine (RI) treatment, and who had 
been followed-up for a mean of 13 months (range, 6-21 months) after the last RI session. 
Combined [18F]-FDG-PET/CT and [124I]-PET/CT data were evaluated for detecting recurrent 
DTC lesions in study patients and compared with those of other radiological and/or 
cytological investigations. Nine of 19 patients (47.4%) showed pathological [18F]-FDG 
(5/19, 26.3%) or [124I]-PET (4/19, 21.1%) uptake, and were classed as true-positives. 
Among such patients, disease management was modified in six (66.7%) and disease was 
restaged in seven (77.8%). In particular, the use of the described imaging combination 
optimized planning of surgical resection to deal with locoregional recurrence in 21.1% 
(4/19) of patients, who were shown to be disease-free during follow-up after surgery. Our 
results indicate that combination of [18F]-FDG-PET/CT and [124I]-PET/CT affords a valuable 
diagnostic method that can be used to make therapeutic decisions in patients with DTC 
who are tumor-free on conventional imaging studies but who have high Tg levels. 
Key Words: [124I]-PET; [18F]-FDG-PET; PET/CT; Elevated Thyroglobulin Levels; Negative [131I] 
Whole-Body Scan; Differentiated Thyroid Carcinoma; Recurrence
Jandee Lee1, Kuk Young Nah2, 
Ra Mi Kim2, Yeon-Ju Oh2, 
Young-Sil An3, Joon-Kee Yoon3, 
Gwang Il An4, Tae Hyun Choi4, 
Gi Jeong Cheon4,5, Euy-Young Soh2, 
and Woong Youn Chung6 
1Department of Surgery, Eulji Medical College Hospital, Seoul; 
2Department of Surgery, Ajou University School of Medicine, 
Suwon; 3Department of Nuclear Medicine, Ajou University 
School of Medicine, Suwon; 4Department of Molecular Imaging, 
Korea Institute of Radiological and Medical Science, Seoul; 
5Department of Nuclear Medicine, Korea University Medical 
Center Anam Hospital, Seoul; 6Department of Surgery, Yonsei 
University College of Medicine, Seoul, Korea
Received: 15 December 2011
Accepted: 2 August 2012
Address for Correspondence:
Woong Youn Chung, MD
Department of Surgery, Yonsei University College of Medicine, 
50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea 
Tel: +82.2-2228-2100, Fax: +82.2-313-8289
E-mail: ljd0906@hanmail.net 
This work was supported by Nuclear Research & Development 
Program of the Korea Science and Engineering Foundation 
(KOSEF) (M20702010001-07N0201-00110) and Quri Project 
grant funded by the Korean government (MEST) (grant code: 
M14943).
http://dx.doi.org/10.3346/jkms.2012.27.9.1019  •  J Korean Med Sci 2012; 27: 1019-1026
ORIGINAL ARTICLE 
Oncology & Hematology
INTRODUCTION
Although the prognosis of patients with differentiated thyroid 
carcinoma (DTC) is favorable, recurrence is noted in up to 30% 
of such patients (1-5). Until recent years, serum thyroglobulin 
(Tg) measurement and the [131I] scan were the mainstays of DTC 
patient evaluation after treatment and during follow-up. The 
[131I] scan has high specificity, yet some of papillary and follicu-
lar thyroid carcinoma recurrences are [131I]-negative (6-9). Be-
cause the most common site of recurrence is the cervical lymph 
nodes, neck ultrasonography (US) may also be helpful in early 
detection of small cervical metastases (10-12). However, a diag-
nostic dilemma is posed by patients who exhibit increased lev-
els of Tg, in the absence of detection of recurrent cancer using 
conventional imaging tools such as the iodine-131 whole-body 
scanning (the [131I] scan) or neck US. Therefore, advanced diag-
nostic imaging permitting anatomical tumor localization has 
been used to accurately detect both iodine- and non-iodine-
avid recurrence; the relevant modalities include positron emis-
sion tomography (PET) using either iodine-124 [124I] or [18F]-flu-
oro-2-deoxy-D-glucose ([18F]-FDG). Moreover, if [18F]-FDG-PET 
and [124I]-PET are both performed before considering whether 
repeated high-dose radioiodine (RI) treatment is appropriate, 
unnecessary RI may be excluded, and further optimal manage-
ment such as surgery or irradiation can be usefully indicated. 
 The benefits of [18F]-FDG-PET to diagnose recurrent and met-
astatic disease, particularly when the [131I] scan is negative, have 
been assessed previously (13-18). The loss of a capacity to con-
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centrate iodine when Tg levels are elevated demand the use of 
imaging tools other than the [131I] scan. Cervical US is another 
valuable tool for treatment of recurrent DTC. However, it is also 
necessary to perform whole-body assessment of disease extent, 
using a different diagnostic technique. Although recurrent or 
metastatic DTC tumors grow rather slowly, such tumors con-
sume more glucose than does normal tissue. Consequently, use 
of [18F]-FDG-PET has been suggested to be valuable in patients 
who are negative (in terms of tumor recurrence) on convention-
al imaging but who show elevated Tg levels. The technique has 
been used to detect both local DTC recurrence and distant me-
tastasis (9, 14-18).  
 Recently, [124I]-PET has emerged as a valuable diagnostic tool 
for the detection of recurrent or residual DTC disease, and the 
data afforded are helpful in the planning of therapy during fol-
low-up of DTC patients (13, 19-23). [124I]-PET imaging may offer 
a higher sensitivity than the conventional [131I] scan because the 
spatial resolution of the former modality is greater. Moreover, 
the recent introduction of combined PET/CT (computed tomog-
raphy) scanners allows thyroid cancers to be imaged using a 
high-resolution PET technique. This may increase the clinical 
application of such imaging in thyroid cancer patients because 
detailed anatomical information is obtained and iodine-posi-
tive tissue can be located (22). 
 The aim of the present study was to prospectively evaluate the 
utility of [18F]-FDG-PET/CT and [124I]-PET/CT in detection of 
recurrent DTC in patients with increasing serum Tg levels but 
who showed no pathological finding upon conventional imag-
ing such as cervical US and the [131I] scan. 
MATERIALS AND METHODS
Inclusion criteria
Between July 2009 and June 2010, 19 patients with histologically 
proven DTC were studied. All patients had previously under-
gone total thyroidectomy and more than one session of postop-
erative RI therapy; the cumulative administered mean dose was 
10,905 MBq (range, 5,500-18,500 MBq). At a mean of 16 months 
(range, 9-41 months) of follow-up after the last RI therapy ses-
sion, all patients showed increasing pathological Tg levels (Tg 
> 9-10 ng/mL) after TSH stimulation (TSH > 30 mU/L). How-
ever, neither tumor recurrence nor metastasis could be detect-
ed in any patient by post-therapeutic [131I] scanning, neck US, 
or chest radiography. Patients with obvious cervical pathology 
in US or positive fine-needle aspiration cytology (FNAC) were 
excluded from the study. 
Study protocol
On the first day (D1) of the study, blood and urine were collect-
ed for routine examination; to measure blood TSH, Tg, and anti-
Tg antibody levels; and to assess urine iodine excretion after 4 
weeks of levothyroxine withdrawal (Fig. 1). All patients had con-
sumed a low-iodine diet for the prior 2 weeks, following written 
instructions and assisted by a dietician. On the second day (D2) 
of the study, an [131I] scan was obtained 48 hr after administra-
tion of 74 MBq of [131I]. On day 10 (D10) of the study, patients 
fasted for at least 4 hr before examination, and were (intrave-
nously) given 370 MBq [18F]-FDG. All patients were instructed 
to rest comfortably for 60 min and to empty the bladder before 
scanning. Whole-body PET/CT images were obtained using a 
Discovery ST scanner (GE Healthcare, Milwaukee, WI). Seven or 
eight frames (3 min/frame) of emission PET data were acquired 
in the two-dimensional mode after noncontrast CT scans had 
been performed from the base of the skull to the upper thigh 
(tube rotation time of 1 sec per revolution; 120 kV; 60 mA; 7.5 
mm per rotation; and an acquisition time of 60.9 sec for a scan 
length of 867 mm). Emission PET images were reconstructed 
via non-contrast CT using an iterative method (ordered-subsets 
expectation maximization with two iterations and 30 subsets; 
field of view 600 mm; slice thickness 3.27 mm). Attenuation-
corrected PET/CT images were reviewed on an Xeleris work-
station (GE Healthcare). All images were independently inter-
preted by two experienced nuclear medicine physicians and 
screened for “hot spots” indicative of hypermetabolic abnor-
malities.
 On day 11 (D11) of the study, 24 hr after administration of an 
[124I] trace dose (74 MBq), whole-body PET/CT scans were ob-
tained using the Discovery ST scanner. The [124I] radioisotope 
was supplied by the Department of Molecular Imaging, Korea 
Institute of Radiological and Medical Sciences (KIRAMS). First, 
a non-enhanced CT scan was performed, from the base of the 
skull to the upper thigh (tube rotation time of 1 sec per revolu-
tion; 140 kV; 80 mA; 3.75 mm per rotation; acquisition time of 
Fig. 1. Diagnostic and therapeutic flow-chart of treatment performed at least 
6 months after high-dose ablation.
Oral administration of 74 MBq131I
Check of Serum Tg-Ag, Tg-Ab
Day (1)
T4 (thyroxine) withdrawal
-Stop thyroid hormone
Day (-28)
D (-28)-D (11)
(18F) FDG-PET/CT after 370 MBq (18F) FDG
Oral administration of 74 MBq124I
Day (10)
Low iodine diet D (-14)-D (11)Day (-14)
131I scanDay (2)
124I-PET/CTDay (11)
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23.9 sec for a scan length of 804 mm). Subsequently, seven or 
eight frames (5 min per frame) of emission PET data were ac-
quired in the two-dimensional mode and reconstructed via CT 
using an iterative method (software from General Electric Med-
ical Systems; ordered-subsets expectation maximization with 
two iterations and 21 subsets; field of view 600 mm; slice thick-
ness 3.27 mm). 
Data analysis
To ensure that the interpretation of [18F]-FDG-PET/CT and [124I]-
PET/CT data was performed under similar conditions, all phy-
sicians who initially read images of one type were deliberately 
blinded to the results of the other type of imaging, and to patient 
clinical data. This was achieved by ensuring that the interpret-
ing physicians were not involved in patient clinical care. Find-
ings on [18F]-FDG-PET and [124I]-PET scanning were compared 
with data from diagnostic and post-therapeutic [131I] scans. More-
over, the data were compared with those of radiological imag-
ing (US, CT, and MRI information), and/or those of cytological 
investigation (FNAC), to confirm (or otherwise) the findings of 
the [131I] scans, and those of both forms of PET/CT (using [18F]-
FDG and [124I]). For each patient, the presence or absence, and 
number and localization of any recurrent lesions (if present) were 
determined. The data of both types of PET/CT scans were classi-
fied as follows: True-positive, if pathologic [18F]-FDG or [124I] up-
take was proven by histology, cytology, or other imaging tech-
niques, and, therefore, lead to a restaging of cancer or a change 
of therapy; False-positive, if pathologic [18F]-FDG or [124I] uptake 
could not verified (such observations were of no clinical conse-
quence); True-negative, if no [18F]-FDG or [124I] uptake was found 
Table 1. Patient characteristics and radiological findings 
Patient No.
Sex/ 
Age (yr)
Operation TNM
RI Tx  
(MBq)
TSH  
(mU/L)
Tg  
(ng/mL)
Tg-Ab  
(U/mL)
[131I] scan 
(post-Tx)
[124I]-PET/
 CT
[18F]-FDG-
PET/CT  
  1 F/28 TT+CCND
(2008.4)
T3N1aM0
(PTC)
6,660 50 18.3 < 30 NS NS FP (op. bed)
  2 F/22 TT+CCND
(2007.8)
T1N1aM0
(PTC)
12,950 90 15.6 < 30 NS NS NS
  3 F/73 TT+CCND
(2005.12)
T3N1aM0
(PTC)
11,100 80 20.2 < 30 NS TP (CLN) NS
  4 F/42 TT+MRND
(2003.10)
T3N1bM0
(PTC)
16,650 92 28.7 108 NS NS TP (trachea)
  5 M/15 TT+MRND
(2007.7)
T3N1bM1
(DS variant)
18,500 > 100 14.6 66 NS TP (MLN) NS
  6 F/33 TT+CCND
(2006.8)
T3N1aM1
(F variant)
9,250 > 100 9.3 < 30 NS NS NS
  7 F/47 TT+MRND
(2006.8)
T3N1bM0
(PTC)
11,100 > 100 17.7 < 30 NS NS NS
  8 M/62 TT+CCND
(2007.7)
T3N1aM0
(PTC)
5,550 > 100 9.5 < 30 NS NS TP (CLN)
  9 M/48 TT+MRND
(2008.10)
T3N1bM0
(PTC)
6,660 62.9 27.9 < 30 NS NS TP (CLN)
10 F/49 TT+CCND
(2007.12)
T3N0M0
(PTC)
5,550 > 100 11.5 < 30 NS NS NS
11 F/82 TT+CCND
(2008.2)
T3N0M0
(FTC)
6,660 > 100 45.8 < 30 NS TP (lung) NS
12 M/43 TT+MRND
(2007.12)
T3N1bM0
(PTC)
12,950 50 16.1 < 30 NS NS FP (CLN)
13 F/24 TT+MRND
(2005.9)  
T3N1bM0
(PTC)
16,650 > 100 97.9 < 30 NS TP (MLN) NS
14 M/38 TT+MRND
(2004.5)  
T4N1bM0
(PTC)
14,800 > 100 18.1 < 30 NS NS FP (CLN)
15 F/73 TT+CCND
(2009.4)
T3N0M0
(FTC)
8,510 45.1 15.3 < 30 NS NS TP (CLN)
16 F/47 TT+CCND
(2009.8)
T3N0M0
(PTC)
7,400 > 100 30.9 115 NS FP (op.bed) NS
17 F/32 TT+MRND
(2009.5)
T3N1bM1
(PTC)
9,250 > 100 86.2 < 30 NS NS NS
18 F/37 TT+MRND
(2008.2)
T3N1bM0
(PTC)
14,800 > 100 22.6 < 30 NS NS NS
19 M/26 TT+MRND
(2008.10)
T3N1bM0
(PTC)
12,210 > 100 35.0 48.0 NS NS TP (CLN)
TT, total thyroidectomy; CCND, central compartment node dissection; NS, no specific finding; FP, false-positive result; PTC, papillary thyroid carcinoma; TP, true-positive result; 
CLN, cervical lymph node; MRND, modified radical neck dissection; DS variant, diffuse sclerosing variant of PTC; MLN, mediastinal lymph node; F variant, follicular variant of 
PTC; FTC, widely invasive follicular carcinoma.
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and the patient had neither an elevated Tg level (Tg ≤ 1 ng/mL 
after TSH elevation) nor any evidence of recurrence upon sub-
sequent follow-up; and, False-negative if no [18F]-FDG or [124I] 
uptake was noted despite elevated Tg levels, even if positive find-
ings were obtained when other imaging methods were employed.
Ethics statement 
The work was reviewed and approved by the institutional review 
board of Ajou University Hospital (#AJIRB-CRO-09-068). Writ-
ten informed consent was obtained from each patient. 
RESULTS
All participants underwent [18F]-FDG-PET/CT and [124I]-PET/
CT between July 2009 and July 2010. No pathological lesion was 
observed in any patient on either the diagnostic or post-thera-
peutic [131I] scans. The study group consisted of 6 males and 13 
females, of a median age of 43 yr (range, 15-82 yr). The charac-
teristics of the 19 participants are listed in Table 1. All patients 
underwent regular follow-up examinations for at least 10 months 
after treatment. 
 Nine of our 19 patients (47.4%) showed pathological [18F]-FDG 
or [124I]-PET uptake, and were classified as true positives. The 
treatment strategies for six of the nine patients (66.7%) were 
changed immediately. In 10 patients (52.6%), no uptake was 
observed on either scan. Validation of the [18F]-FDG-PET/CT 
and [124I]-PET/CT findings is summarized in Table 1. 
[18F]-FDG-PET/CT vs [124I]-PET/CT 
Eight patients showed uptake by [18F]-FDG-PET; however, only 
five patients (62.5%) were true positives. Two patients underwent 
further surgery, whereas three received high-dose RI therapy 
after preparation with retinoic acid. Also, [18F]-FDG-PET cor-
rectly restaged three of five patients (60.0%). In contrast, the re-
maining three patients (37.5%) were false-positives upon FDG-
PET imaging. This was confirmed by histological findings or via 
use of other radiological information, and subsequent measure-
ment of Tg levels during follow-up. The details of the additional 
radiological imaging tests conducted (neck CT/MRI, chest CT, 
or FNAC) are listed in Table 2. Fig. 2 shows [18F]-FDG-PET/CT 
Table 2. Clinicopathological characteristics and treatment outcomes of patients with FDG-PET- or [124I]-PET-positive recurrence   
Patient No.
Sex/ 
age (yr)
PET PET/CT Lesion
Additional imaging 
studies
Stage change Treatment change
FDG-PET(+) and [124I]-PET(-) findings
    4
    8
    9
  15
  19
 
F/42
M/62
M/48
F/73
M/26
 
FN
TP
FN
TP
TP
 
TP
TP
TP
TP
TP
 
Trachea
Cervical LN
Cervical LN
Paratracheal LN
Cervical LN
 
Neck US, neck CT
Neck US with FNAC
Neck US, neck CT
Neck US, neck CT
Neck US with FNAC
 
T3 → T4a 
N1a → N1b
No
N0 → N1a
No
 
Yes (retinoic acid with high dose RI)
Yes (surgery)
Surgery refused 
Yes (retinoic acid with high dose RI)
Yes (retinoic acid with high dose RI)
Yes (surgery)
[124I]-PET(+) and FDG-PET(-) findings
    3
    5
  11
  13
 
F/73
M/15
F/82
F/24
 
TP
FN
TP
TP
 
TP
TP
TP
TP
 
Cervical LN
Mediastinal LN
Lung
Mediastinal LN
 
Neck US, FNAC
Neck CT
Chest CT
Neck US, FNAC
 
N1a → N1b
T3 → T4a
M0 → M1
T3 → T4b
 
Yes (surgery)
No (high-dose RI)
No (high-dose RI)
No (high-dose RI); Surgery refused
FN, false-negative result; TP, true-positive result; RI, radioactive iodine treatment. 
A B
Fig. 2. Patient 8: [18F]-FDG-PET/CT data from a patient with an elevated Tg level but who was tumor-negative on both neck US and a post-therapy [131I] scan. [131I]-negative [18F]-
FDG-positive metastases are evident in the cervical lymph node (A), and the CT scan affords exact localization (B).
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images of a patient who had an elevated Tg level but who was 
devoid of any definite within-tissue [131I] concentration post-ther-
apeutically. No definite [131I]-positive lesion was found, but [18F]-
FDG-PET-positive cervical lymph node metastasis was detect-
ed, and precisely located via image fusion with CT scan data.
 Five patients showing uptake on [124I]-PET/CT scans had le-
sions that were not visible on post-treatment [131I] scans. Of these 
patients, four (80.0%) were confirmed to have recurrence, using 
either histological or other radiological means. One patient un-
derwent further surgery and three received high-dose radiation 
therapy. Moreover, [124I]-PET correctly restaged all four patients. 
A false-positive finding was recorded for only one patient; the 
FNAC test and other imaging data were negative. Fig. 3 shows 
data on a patient in whom a small cervical lymph node metas-
tasis was not seen upon post-therapeutic [131I] ablation scanning 
or neck US, but was clearly identified in the [124I]-PET/CT image. 
Fig. 4 shows that metastasis localization is improved upon use 
of [124I]-PET compared with conventional imaging, indicating 
that lung metastasis not found upon post-therapeutic [131I] scan-
ning or chest radiography was visible in the [124I]-PET scan. Also, 
in three patients (patients 4, 5, and 9) both types of PET/CT, thus 
using either [18F]-FDG or [124I], were more accurate in terms of 
disease localization than was PET scanning alone, and the PET/ 
CT results caused the treatment of patients 4 and 9 to be changed 
(Table 2).
Treatment modalities and follow-up
Based on radiological findings, 15.8% (3/19) of all patients un-
derwent surgery. One patient was negative on [18F]-FDG-PET/
CT but showed metastasis on [124I]-PET/CT, whereas the other 
two patients exhibited local recurrence only on [18F]-FDG-PET/
CT. These patients were all disease-free on further follow-up. 
Tumor response was demonstrated during follow-up (Table 3). 
The treatment outcomes were: stable disease in six patients, re-
Fig. 3. Patient 3: [124I]-PET/CT data from a patient with an elevated Tg level but who was tumor-negative on both neck US and a post-therapy [131I] scan. (A) The post-therapy 
[131I] scan did not clearly reveal the cervical lymph node metastasis evident on the [124I]-PET scan. (B) Exact localization of the lesions of lateral lymph node metastasis, obtained 
by fusion of the image with that of the CT scan.
A B
Fig. 4. Patient 11: [124I]-PET showed that lung metastases were present; the patient had widely invasive follicular carcinoma. In this patient, no definite positive lesion was evi-
dent upon either the diagnostic or post-therapy [131I] scans, despite the presence of an elevated Tg level. The [124I]-PET scan showed definite lung metastases (A), and [124I]-PET/
CT precisely localized the lesions (B). 
A B
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gressive disease in eight, progressive disease in two, and disease-
free status in all three patients who underwent surgical treatment. 
DISCUSSION
This is the initial report on the results of a prospective study on 
the effectiveness of PET/CT using both [124I] and [18F]-FDG to 
locate recurrent DTC lesions in patients with elevated thyro-
globulin levels but who do not show pathological lesions when 
conventional imaging modalities are used. The present study 
showed that the use of a combination of [124I]-PET/CT and [18F]-
FDG-PET/CT revealed the complete extent of the disease and 
afforded precise anatomical localization of iodine-positive and 
iodine-negative lesions in 9 of the 19 patients (47.4%). Thus, if 
[18F]-FDG-PET/CT and [124I]-PET/CT were performed before 
repeated high-dose RI treatment was considered, such an eval-
uation would facilitate diagnostic accuracy and might avoid un-
necessary exposure of patients to radiation. 
 Some patients showed increased levels of Tg but convention-
al imaging tests (the [131I] scan, neck US, and/or chest radiogra-
phy) do not reveal a pathological lesion. Therefore, other meth-
ods were required to locate the disease. In patients with elevat-
ed Tg levels, empirical high-dose RI treatment may be indicat-
ed, followed by a post-treatment [131I] scan; this is also a useful 
diagnostic method. However, repeated empirical treatment with 
RI may unnecessarily expose patients to high levels of radiation; 
this may be a particular problem in patients who show no [131I] 
uptake on the post-treatment scan (7-9, 14-18). Therefore, an 
advanced diagnostic imaging technique, such as [124I]-PET/CT 
or [18F]-FDG-PET/CT, that provides anatomical localization data, 
is required. The information provided by such scans is necessary 
to allow physicians to accurately locate metastatic lesions and 
to indicate the most efficient therapeutic options. In our patient 
series, we showed that combination PET/CT using [124I] and [18F]-
FDG was more accurate in terms of lesion localization than was 
conventional imaging, in 9 of our 19 patients (47.4%).  
 Currently, [18F]-FDG-PET/CT is recognized as useful in ex-
amination of DTC patients who present with negative [131I] scan 
data but pathologically increased Tg levels (14-18). Moreover, 
any difference between PET findings and conventional [131I] 
scan information can provide important clinical clues relevant 
to treatment of recurrent DTC. However, no complete consen-
sus has yet been achieved on whether [18F]-FDG-PET/CT has a 
diagnostic utility independent of that of Tg level, or even if the 
scan data are associated with Tg concentration. Some authors 
have reported that TSH elevation seems to improve scan sensi-
tivity. In such patients, the incremental value afforded by hor-
monal stimulation of TSH is great because lesions that might be 
missed owing to their small size or low metabolic activity become 
apparent (25, 26). This is why TSH significantly increases [18F]-
FDG uptake in DTC patients experiencing recurrence; TSH stim-
ulates GLUT-1 expression and thus indirectly increases glucose 
transport. The stimulation afforded by TSH is real. However, 
other reports found no increase in the accuracy (sensitivity) of 
scan data obtained after hormonal TSH stimulation (27, 28). 
Accordingly, no consensus on the effect of TSH stimulation on 
FDG-PET accuracy has been attained and it is important to ren-
der scanning cost-effective (18). In the present study, the results 
Table 3. Treatment methods and status at last follow-up
Patient No.
Sex/ 
age (yr)
[124I]-positive 
(iodine-avidity)
FDG-positive  
(non-iodine avidity)
Treatment method
Follow-up duration 
(months)
Status at last follow-up
  1 F/28 NS FP Wait and watch 23 Stable disease
  2 F/22 NS NS Wait and watch 23 Stable 
  3 F/73 TP NS Surgery (MRND) 22 Disease-free
  4 F/42 NS TP RI treatment (150 mCi, with retinoic acid) 22 Regressive 
  5 M/15 TP NS RI treatment (200 mCi) 21 Stable 
  6 F/33 NS NS Wait and watch 20 Regressive 
  7 F/47 NS NS RI treatment (300 mCi) 20 Regressive
  8 M/62 NS TP Surgery (SLD) 20 Disease-free
  9 M/48 NS TP RI treatment (250 mCi ,with retinoic acid) 19 Regressive
10 F/49 NS NS Wait and watch 18 Regressive
11 F/82 TP NS RI treatment (250 mCi) 18 Stable
12 M/43 NS FP RI treatment (200 mCi) 17 Regressive
13 F/24 TP NS RI treatment (250 mCi) 17 Stable 
14 M/38 NS FP RI treatment (300 mCi) 16 Progressive
15 F/73 NS TP RI treatment (150 mCi, with retinoic acid) 15 Regressive
16 F/47 FP NS RI treatment (150 mCi) 15 Stable 
17 F/32 NS NS RI treatment (300 mCi) 12 Progressive
18 F/37 NS NS RI treatment (150 mCi) 11 Regressive
19     M/26 NS TP Surgery (SLD) 10 Disease-free
SLD, selective lymph node dissection; Disease-free, Negative on any kind of imaging study and serum Tg ≤ 1 ng/mL (TSH stimulation); Regressive, Reduced tumor volume on 
imaging study or decreased serum Tg level; Stable, No change on imaging study and serum Tg level; Progressive, Expanded tumor volume on imaging study or increased serum 
Tg level. 
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of PET/CT using [18F]-FDG after TSH stimulation increased di-
agnostic confidence, resulted in less uncertainty than is associ-
ated with interpretation of the data of conventional imaging; 
yielded additional information on approximately 26.3% of pa-
tients (5/19), and triggered changes in therapeutic management 
of all such patients (for example, patient 8; Fig. 2). 
 Iodine-124 is a positron-emitting isotope and is therefore suit-
able for use in PET imaging. The half-life is 4.2 days and the de-
cay scheme is complex, resulting in additional radiation coinci-
dence detection that is either non-destructive in terms of image 
quality or partially destructive (29, 30). Recently, the isotope has 
been used for thyroid cancer imaging using high-resolution PET, 
and a combination of [124I]-PET and CT increased the clinical 
application of such a modality in thyroid cancer patients; detailed 
anatomical information and the location of iodine-positive tis-
sue are provided (19-22, 29, 30). The [124I] isotope has also been 
used in dosimetric studies and for thyroid volume measurement 
(13, 20-23). Most reports found that [124I]-PET scanning was use-
ful in terms of DTC staging before RI treatment, and did not ma-
terially affect the therapeutic radiation dose (18, 20-23). Only a 
few studies have to date evaluated the efficacy of [124I]-PET in 
localization of tumor recurrence during follow-up of DTC pa-
tients after ablation (19-21). Therefore, we focused on this topic. 
We found that the combination of [124I]-PET with CT consider-
ably (21.1%; 4/19 patients) improved the ability to detect recur-
rent lesions compared with conventional imaging.
 Why is [124I]-PET/CT an appropriate diagnostic method when 
empirical high-dose RI treatment is recognized to be valuable 
in clinical practice? RI treatment of patients negative on the low-
dose diagnostic [131I] scan but with elevated Tg levels has been 
used diagnostically, therapeutically, and prognostically (21). In 
addition, patients who show no iodine accumulation on post-
treatment [131I] scanning (which may indicate tumor dediffer-
entiation) have a poorer prognosis than do others (31). However, 
repeat high-dose RI treatment may be associated with a long-
term risk of secondary malignancy or infertility. The total radia-
tion exposure during an [124I]-PET scan has been calculated to 
be 7.0 mSv, at a dose of 74 MBq [124I]. This is similar to the dose 
used in routine nuclear medicine scans. However, the total ex-
posure to [124I] is very low compared with that from the therapeu-
tic dose of [131I] (340 mSv from a dose of 5,500 MBq) (31). There-
fore, if [124I]-PET/CT is performed before empirical repeat RI 
treatment, the total radiation exposure is markedly decreased. 
Our results show that such an approach avoids unnecessary de-
livery of high-dose radiation to patients with recurrence when 
existing locoregional metastases are not detected by the [131I] scan 
(for example, in patient 3; Fig. 3). The technique yields useful 
information when the iodine-avidity of a distant metastatic re-
gion has not previously been reliably assessed (for example, in 
patient 11; Fig. 4). 
 Our study had several limitations. First, we enrolled only a 
small number of participants, and a large prospective trial is re-
quired to definitively evaluate our data. Second, our follow-up 
period was relatively short; years or decades of follow-up must 
pass before statistically reliable data can be obtained; this reflects 
the epidemiological and prognostic features of DTC. Finally, it 
is important to establish uniform standards for the conduct of 
scans, and to develop guidelines permitting comprehensive in-
terpretation of test results, before the possible superiority of our 
[18F]-FDG-PET-plus-[124I]-PET combination can be precisely 
compared with traditional follow-up protocols. The technique 
should be offered to only well-informed patients who thorough-
ly understand the advantages, limitations, and downside of de-
termining cancer location. Our further studies will address these 
issues. Also, the histopathological and cytopathological charac-
teristics associated with the ability of a tumor to avidly take up 
iodine, glucose, or both, require investigation. 
 Our findings showed that both [124I]-PET/CT and [18F]-FDG-
PET/CT are useful diagnostic tools when recurrence occurs in 
DTC patients who have elevated Tg levels but no definitive ab-
normalities by conventional imaging. Moreover, a combination 
of the two modalities provides an even greater diagnostic capac-
ity, by which therapeutic decisions on additional surgery or RI 
treatment can be informed. However, it should be also noticed 
that considerable number of patients could not be detected by 
these imaging techniques, and therefore, continuing and fur-
ther studies are still required.
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